EPIOMIC EPIDEMIOLOGY SERIES: ACUTE DECOMPENSATED HEART FAILURE FORECAST IN 12 MAJOR MARKETS 2017-2027

EPIOMIC EPIDEMIOLOGY SERIES: ACUTE DECOMPENSATED HEART FAILURE FORECAST IN 12 MAJOR MARKETS 2017-2027

  • October 2017 •
  • 53 pages •
  • Report ID: 5178762 •
  • Format: PDF
Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Acute Decompensated Heart Failure in 12 Major Markets

Acute decompensated heart failure (ADHF), a sub-set of chronic heart failure (CHF), is a life-threatening episode during which the heart is not able to supply sufficient blood flow to the body. This requires urgent medical attention. The condition is divided into two subtypes: ADHF with reduced (ADHF-REF) and preserved (ADHF-PEF) ejection fraction. HF is characterized by dyspnoea at rest or on exertion and worsening fluid retention, apparent as lung congestion and/or swollen ankles and legs.

This report provides the current prevalent population for ADHF across 12 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Japan, China, Russia, Brazil, India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, ADHF-REF and ADHF-PEF patients have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot. Moreover, a forecast of ADHF patient populations demonstrating main comorbidities has been included.

Main co-morbidities for ADHF include:
• Diabetes
• COPD
• Anaemia
• Atrial fibrillation
• Coronary artery disease

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy
• Able to quantify patient populations in global ADHF market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of ADHF and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on ADHF prevalent population.
• Identify sub-populations within ADHF which require treatment.
• Gain an understanding of the specific markets that have the largest number of ADHF patients.
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.